FDA lifts clinical hold on Solid's DMD gene therapy

Solid Biosciences Inc. (NASDAQ:SLDB) said FDA lifted a clinical hold on the Phase I/II IGNITE DMD trial of microdystrophin gene transfer therapy SGT-001 to treat Duchenne muscular dystrophy (DMD). Solid plans to

Read the full 320 word article

User Sign In